Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius® Test that helps clinicians make rapid treatment decisions.
Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Karius was founded in 2014 by Mickey Kertesz and Tim Blauwkamp. The company is headquartered in Redwood City, California.
Karius uses genomics and AI to map a patient’s microbial landscape from a single blood draw, moving closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
Karius pioneered the discovery and application of microbial cell-free DNA, enabling non-invasive detection of pathogens throughout the body with its Karius® Test. Today, the Karius Test is used in over 100 hospitals and health systems nationwide.
Karius is backed by Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Khosla Ventures, LightSpeed Venture Partners, Oxford Finance LLC and others. The company raised $165M in a Series B round on Feb 24, 2020. This brings Karius' total funding to $254M to date.